SLRX
Income statement / Annual
Last year (2024), Salarius Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Salarius Pharmaceuticals, Inc.'s net income was -$5.58 M.
See Salarius Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$5.23 M |
$3.47 M |
$838.14 K |
$1.27 M |
$1.01 M |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$430.75 K
|
$506.53 K
|
$662.75 K
|
$49.88 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.23 M
|
$3.47 M
|
$407.39 K
|
$767.97 K
|
$347.92 K
|
-$49.88 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0.99
|
1
|
1
|
0.49
|
0.6
|
0.34
|
0
|
| Research and Development Expenses |
$770.03 K
|
$7.17 M
|
$15.84 M
|
$8.55 M
|
$6.91 M
|
$4.02 M
|
$11.91 M
|
$16.99 M
|
$20.38 M
|
$12.75 M
|
| General & Administrative Expenses |
$4.96 M
|
$5.72 M
|
$7.14 M
|
$6.10 M
|
$6.11 M
|
$7.71 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.96 M
|
$5.72 M
|
$7.14 M
|
$6.10 M
|
$6.11 M
|
$7.71 M
|
$10.57 M
|
$18.50 M
|
$19.86 M
|
$16.46 M
|
| Other Expenses |
$0.00
|
$0.00
|
$8.87 M
|
-$1.84 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$5.73 M
|
$12.89 M
|
$31.84 M
|
$12.81 M
|
$13.02 M
|
$11.73 M
|
$22.48 M
|
$35.49 M
|
$40.23 M
|
$29.21 M
|
| Cost And Expenses |
$5.73 M
|
$12.89 M
|
$31.84 M
|
$12.81 M
|
$13.02 M
|
$11.73 M
|
$22.91 M
|
$36.00 M
|
$40.90 M
|
$29.21 M
|
| Interest Income |
$158.54 K
|
$352.25 K
|
$218.73
|
$0.00
|
$0.00
|
$15.65 K
|
$152.01 K
|
$291.96 K
|
$393.11 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.05 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$4.42 K
|
$10.05 K
|
$6.68 K
|
$19.18 K
|
$18.06 K
|
$127.41 K
|
$228.16 K
|
$324.55 K
|
$277.23 K
|
$49.88 K
|
| EBITDA |
-$5.73 M |
-$12.88 M |
-$22.97 M |
-$12.79 M |
-$7.59 M |
-$8.14 M |
-$21.85 M |
-$34.40 M |
-$39.61 M |
-$29.09 M |
| EBITDA Ratio |
0
|
0
|
0
|
-12768238
|
-1.45
|
-2.35
|
-26.06
|
-26.99
|
-39.19
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
-6.96
|
-1.49
|
-2.39
|
-26.34
|
-27.25
|
-39.47
|
0
|
| Total Other Income/Expenses Net |
$158.54 K
|
$352.25 K
|
$233.18 K
|
$44.69 K
|
$434.09 K
|
$1.33 M
|
$152.01 K
|
$291.96 K
|
$393.11 K
|
$72.00 K
|
| Income Before Tax |
-$5.58 M
|
-$12.54 M
|
-$31.61 M
|
-$12.77 M
|
-$7.35 M
|
-$6.94 M
|
-$21.92 M
|
-$34.43 M
|
-$39.49 M
|
-$29.14 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
-6.94
|
-1.4
|
-2
|
-26.16
|
-27.02
|
-39.08
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$630.00
|
| Net Income |
-$5.58 M
|
-$12.54 M
|
-$31.61 M
|
-$12.77 M
|
-$7.35 M
|
-$6.94 M
|
-$21.92 M
|
-$34.43 M
|
-$39.49 M
|
-$29.14 M
|
| Net Income Ratio |
0
|
0
|
0
|
-6.94
|
-1.4
|
-2
|
-26.16
|
-27.02
|
-39.08
|
0
|
| EPS |
-86.85 |
-0.057 |
-221.55 |
-930 |
-1500 |
-6360 |
-91500 |
-149250 |
-182250 |
-19468.8 |
| EPS Diluted |
-86.85 |
-0.057 |
-221.55 |
-930 |
-1500 |
-6360 |
-91500 |
-149250 |
-182250 |
-19468.8 |
| Weighted Average Shares Out |
$64.47 K
|
$218.73 K
|
$142.34 K
|
$13.80 K
|
$5.22 K
|
$1.09 K
|
$1.21 M
|
$1.16 M
|
$1.09 M
|
$1.50 K
|
| Weighted Average Shares Out Diluted |
$64.47 K
|
$218.73 K
|
$142.34 K
|
$13.86 K
|
$5.22 K
|
$1.09 K
|
$1.21 M
|
$1.16 M
|
$1.09 M
|
$1.50 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
